The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,092.00
Ask: 12,096.00
Change: 46.00 (0.38%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,106.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Global stocks advance on coronavirus treatment hopes, dollar gains

Mon, 24th Aug 2020 21:12

(Adds close of U.S. markets)

* S&P 500, Nasdaq set all-time peaks

* Apple shares cross $500, Alibaba at record high

* Dollar gains on optimism over COVID-19 treatments

* Gulf of Mexico storms lift crude oil futures

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

By Herbert Lash

NEW YORK, Aug 24 (Reuters) - A gauge of global equity
markets raced toward a record high on Monday in a rally that
lifted the S&P 500 and Nasdaq to all-time peaks and buoyed the
dollar as hopes for coronavirus treatments bolstered risk
appetite.

U.S. regulators on Sunday authorized the use of blood plasma
from recovered COVID-19 patients as a treatment option. Shares
of AstraZeneca rose on a Financial Times report that the U.S.
government was considering fast-tracking its experimental
vaccine.

The U.S. Food and Drug Administration's move to give
emergency authorization for the use of anti-body rich plasma was
hailed by President Donald Trump. It came a day after he accused
the FDA of impeding the roll-out of treatments until after the
Nov. 3 presidential election.

The World Health Organization was cautious about endorsing
the use of the plasma to treat those who are ill, saying
evidence that it works remains "low quality."

The announcement came on the eve of the Republican National
Convention. Trump on Monday received enough votes to formally
win the nomination as the Republican candidate for the
presidency for another four years.

Progress in treatments or an effective vaccine to gain
control of the virus would aid Trump's re-election chances.

Craig Erlam, senior market analyst at OANDA in London, said
that while it was a highly political move on Trump's part,
"everyone wants to be the first to market, everyone wants to get
the economy back on track and slow down the death rate."

"When you add it all up, it's positive COVID news for the
market," he said.

Equity markets worldwide rose on the vaccine hopes. Europe's
broad FTSEurofirst 300 index closed up 1.62% at
1,439.54, while MSCI's all-country world index
rose 1.06% to 577.02 after overnight gains in Asia.

The benchmark for global equity markets is less than 1%
from scaling its all-time peak reached in February.

AstraZeneca rose 2.1%, providing the FTSE 100
index in London its biggest boost.

Shares of Apple Inc rose 1.3% to cross $500 for the
first time, while Chinese retailer Alibaba's U.S.-listed shares
climbed 3.8%, to a record high. Shares of electric
carmaker also set a new high before retreating 1.8%.

On Wall Street, the Dow Jones Industrial Average rose
1.35%, the S&P 500 gained 1.00%, and the Nasdaq Composite
added 0.6%.

The dollar edged higher, holding above two-year lows against
the euro, as its sell-off against the single currency paused
after the U.S. currency got a boost on Friday. Data showed a
recovery in U.S. business conditions, while European data showed
slowing improvement.

Federal Reserve Chairman Jerome Powell this week will give a
highly anticipated speech about the U.S. central bank's policy
framework review at the Fed's annual Jackson Hole symposium.

The speech will be watched for clues about interest rates
and will likely be the next major dollar driver, with investors
watching to see if Powell signals that the Fed will shift its
inflation target to an average.

The 10-year U.S. Treasury note rose 1.4 basis
points to 0.6542%.

The dollar index rose 0.113%, with the euro
down 0.05% to $1.1789.

The Japanese yen weakened 0.12% versus the greenback
at 105.96 per dollar.

Oil prices strengthened as storms threatening the Gulf of
Mexico shut more than half of the U.S. region's oil production
and on expectations of progress in the development of a COVID-19
treatment.

Brent crude futures settled up 78 cents at $45.13 a
barrel. U.S. crude futures rose 28 cents to settle at
$42.62 a barrel.

Gold prices fell as optimism over the FDA's authorization of
a COVID-19 treatment lifted Wall Street stocks to record highs.
U.S. gold futures settled down 0.4% at $1,939.20 an
ounce.

(Reporting by Herbert Lash; Editing by Dan Grebler and Leslie
Adler)

More News
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.